NY-BOTIFY
Botify, the leading enterprise software company for performance-driven organic search, is closing out 2022 by appointing a series of global executive hires and company advisors. The decision comes in response to continued industry and company growth, illustrating the company’s commitment to driving innovation, delivering excellence across all areas of the business and supporting customers with every opportunity to leverage organic search as a high-impact performance marketing channel.
“I’m thrilled to welcome Brian Marin, Phil Young, Vincent Gonnot, A.J. Ghergich, and Steve Sadove to Botify as we expand how we help global brands improve how they are found in organic search,” said Botify CEO, Adrien Menard. “Each of these leaders will be extremely instrumental in supporting our continued growth and new announcements in the coming months. As we embrace widespread recognition of the impact organic search has on company performance, and define Botify’s next chapter to meet growing demand, I’m confident that together, we will do great things.”
Former Smartly.io executive Brian Marin joined in August as Senior Vice President of Global Services. In this newly created role, Marin will launch a consulting service practice and expand professional services to meet continued customer demand. A seasoned digital marketer, Marin brings decades of SaaS experience and a proven track record building and leading services functions for companies in hyper-growth mode.
Joining Marin’s growing team, Botify welcomed A.J. Ghergich as Vice President of Consulting Services to lead the rollout of Botify’s new consulting service offering. Ghergich brings more than 15 years of organic search and digital marketing experience consulting for Fortune 500 global brands.
Phil Young, Vice President of Sales of Northern Europe, joined Botify in July, focusing on leading sales teams across Northern Europe including the UK, Denmark, Finland, Sweden, and the Netherlands. Young will be working closely with the marketing and product teams to drive growth and ensure the highest success level for his teams. Young brings more than 25 years’ experience driving sales results and joins Botify from Sitecore, the leading provider of end-to-end digital experience software, where he was Area Vice President of Northern EMEA.
Focusing on European expansion, Vincent Gonnot also joined Botify as Vice President of Sales Central/South EMEA in December. Similar to Young, Gonnot will be working alongside the marketing and product teams to ensure optimal regional growth for the company. Gonnot has more than 20 years of international sales and management experience across large companies and startups.
Additionally, Steve Sadove, Principal at Stephen Sadove and Associates, has joined Botify as an advisor, helping to provide high-level counsel to inform the company’s continued growth trajectory. Throughout his career serving as CEO of several retail and consumer brands, Sadove has mastered a deep understanding of how leveraging the right technologies can transform the entire landscape for a business. He will be instrumental in helping Botify achieve amplified success as an essential solution across global organizations.
About Botify
Botify is a global, enterprise software company focused on enabling the most ambitious brands to leverage organic search as a high-impact, performance marketing channel. Powered by AI and a proprietary unified data model, Botify’s platform ensures web and mobile sites are optimized for search, the foundation of being found by consumers in today’s dynamic digital environment. As the leader in organic search innovation, Botify is trusted by more than 500 of the world’s most visible brands, including Expedia, L'Oréal, Crate & Barrel, and The New York Times, all of whom have succeeded in leveraging organic search for exponential, long-term results and revenue growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005241/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom